Inventor
ZUGMAIER GERHARD
DE13 patents
⚠️ This page may combine multiple inventors who share the name “ZUGMAIER GERHARD”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
AMGEN RES MUNICH GMBH
9 patentsUS9688760B2Jun 27, 2017
Anti-leukocyte adhesion for the mitigation of potential adverse events caused by CD3-specific binding domains
AMGEN RES MUNICH GMBH17 citations90
US10662243B2May 26, 2020
Dosage regimen for administering a CD19XCD3 bispecific antibody
AMGEN RES MUNICH GMBH6 citations82
US11597766B2Mar 7, 2023
Treatment of acute lymphoblastic leukemia
AMGEN RES MUNICH GMBH8 citations77
US10696744B2Jun 30, 2020
Means and methods for treating DLBCL
AMGEN RES MUNICH GMBH3 citations72
US11084876B2Aug 10, 2021
Anti-leukocyte adhesion for the mitigation of potential adverse events caused by CD3-specific binding domains
AMGEN RES MUNICH GMBH4 citations71
US9486475B2Nov 8, 2016
PPS for the prevention of potential adverse effects caused by CD3 specific binding domains
AMGEN RES MUNICH GMBH4 citations71
US11633408B2Apr 25, 2023
Prevention of adverse effects caused by CD3 specific binding domains
AMGEN RES MUNICH GMBH0 citations61
US11079381B2Aug 3, 2021
Risk-stratification of B-precursor acute lymphoblastic leukemia patients
AMGEN RES MUNICH GMBH0 citations56
US11053318B2Jul 6, 2021
Administration of a bispecific construct binding to CD33 and CD3 for use in a method for the treatment of myeloid leukemia
AMGEN RES MUNICH GMBH1 citations56